Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Purinergic signaling is a form of extracellular signaling mediated by purine nucleotides and nucleosides, primarily adenosine triphosphate (ATP) and adenosine (ADO). These molecules act as signaling messengers by binding to specific membrane receptors on the surface of the same cell (autocrine) or neighboring cells (paracrine), thereby regulating a wide range of cellular functions. It involves P1 receptors (A1, A2A, A2B, and A3) that respond to adenosine and P2 receptors that respond to ATP and ADP, further subdivided into P2X (ligand-gated ion channels) and P2Y (G-protein–coupled receptors). Dysregulation is implicated in numerous diseases, offering potential therapeutic targets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Purinergic Signaling Pathway.